Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/81423
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLee, M.en
dc.contributor.authorFraser, J.en
dc.contributor.authorChapman, M.en
dc.contributor.authorSundararajan, K.en
dc.contributor.authorUmapathysivam, M.en
dc.contributor.authorSummers, M.en
dc.contributor.authorZaknic, A.en
dc.contributor.authorRayner, C.en
dc.contributor.authorMeier, J.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorDeane, A.en
dc.date.issued2013en
dc.identifier.citationDiabetes Care, 2013; 36(10):3333-3336en
dc.identifier.issn0149-5992en
dc.identifier.issn1935-5548en
dc.identifier.urihttp://hdl.handle.net/2440/81423-
dc.description.abstractOBJECTIVE Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have additive insulinotropic effects when coadministered in health. We aimed to determine whether GIP confers additional glucose lowering to that of GLP-1 in the critically ill. RESEARCH DESIGN AND METHODS Twenty mechanically ventilated critically ill patients without known diabetes were studied in a prospective, randomized, double-blind, crossover fashion on 2 consecutive days. Between T₀ and T₄₂₀ minutes, GLP-1 (1.2 pmol/kg • min−1) was infused intravenously with either GIP (2 pmol/kg • min⁻¹) or 0.9% saline. Between T₆₀ and T₄₂₀ minutes, nutrient liquid was infused into the small intestine at 1.5 kcal/min. RESULTS Adding GIP did not alter blood glucose or insulin responses to small intestinal nutrient. GIP increased glucagon concentrations slightly before nutrient delivery (P = 0.03), but not thereafter. CONCLUSIONS The addition of GIP to GLP-1 does not result in additional glucose-lowering or insulinotropic effects in critically ill patients with acute-onset hyperglycemia.en
dc.description.statementofresponsibilityMichael Y. Lee, Jonathan D. Fraser, Marianne J. Chapman, Krishnaswamy Sundararajan, Mahesh M. Umapathysivam, Matthew J. Summers, Antony V. Zaknic, Christopher K. Rayner, Juris J. Meier, Michael Horowitz, Adam M. Deaneen
dc.language.isoenen
dc.publisherAmer Diabetes Assocen
dc.rights© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.en
dc.subjectHumans; Hyperglycemia; Critical Illness; Gastric Inhibitory Polypeptide; Blood Glucose; Prospective Studies; Cross-Over Studies; Double-Blind Method; Adult; Aged; Middle Aged; Female; Male; Glucagon-Like Peptide 1en
dc.titleThe effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically illen
dc.typeJournal articleen
dc.identifier.rmid0020132186en
dc.identifier.doi10.2337/dc13-0307en
dc.identifier.pubid17758-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidChapman, M. [0000-0003-0710-3283]en
dc.identifier.orcidRayner, C. [0000-0002-5527-256X]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidDeane, A. [0000-0002-7620-5577]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_81423.pdfPublished version317.28 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.